Diabetes Drug, Metformin, Recalled for Cancer-Causing Contamination
On June 11, 2020, the FDA announced that five pharmaceutical companies would be voluntarily recalling certain extended-release metformin drugs (ERM) used in the treatment of type 2 diabetes. This announcement came two weeks following the FDA’s initial recall recommendation after agency testing of ERM revealed unacceptable levels of N-Nitrosodimethylamine (NDMA), a human carcinogen. A Recurring
On June 11, 2020, the FDA announced that five pharmaceutical companies would be voluntarily recalling certain extended-release metformin drugs (ERM) used in the treatment of type 2 diabetes. This announcement came two weeks following the FDA’s initial recall recommendation after agency testing of ERM revealed unacceptable levels of N-Nitrosodimethylamine (NDMA), a human carcinogen.
A Recurring Culprit: NDMA
The World Health Organization (WHO) classifies N-Nitrosodimethylamine (NDMA) as a probable human carcinogen. N-nitrosamines, naturally occurring environmental toxins, generally form “when a secondary or tertiary amine reacts with a nitrosating agent.” Low levels of NDMA are found in roasted meats, cheese, beer, and other foods due to cooking and fermentation processes. As a carcinogen, NDMA has been associated with cancers of the liver, pancreas, kidney, bladder, stomach, colon, blood, and ovaries. NDMA has also been linked to non-Hodgkin’s lymphoma and multiple myeloma.
Metformin on the U.S. Market
Metformin is a prescription drug that aids high blood sugar regulation in patients with type 2 diabetes, a disease impacting 1 in 10 Americans. Metformin has been widely prescribed—78.6 million prescriptions were written in 2017 alone—and considered to be one of the safest drugs on the market for managing diabetes. Patients have been attracted to the extended release version in particular for its once-daily dosage, while the immediate release formulation must be taken twice a day. But even in the wake of the recall, pharmacy industry experts have commented that metformin should not be considered totally unsafe now. Rather, the FDA’s testing has indicated only certain lots of ERM were impacted. The current consensus points towards a flaw in the manufacturing process as the source of NDMA, though details of the contamination are still under investigation.
Detecting Danger Abroad
Prior to the FDA’s metformin recall announcements, other countries were already monitoring the drug’s safety. In 2019, the Health Sciences Authority of Singapore (HSA) discovered NDMA contamination in some types of metformin drugs. This led to a December 2019 recall of certain extended release tablets manufactured by Pharmazen Medicals Pte. Ltd. and Glorious Dexa Singapore.
In February 2020, Canadian officials announced recalls of certain lots of Apotex’s ERM tablets and six ERM lots from Ranbaxy Pharmaceuticals. The studies underlying these recalls prompted authorities in Europe and the U.S. to start looking into potential contamination in ERM products in their respective markets. However, an initial FDA study announced in February 2020 showed no instances where NDMA levels exceeded the acceptable daily intake limit of 96 nanograms.
But it was an NDMA discovery by a private laboratory company that caught the FDA’s attention. The Connecticut-based company, Valisure, observed more than 10 times the accepted level of NDMA in several tested batches of metformin. Further, researchers found there was significant batch to batch variability, even within a single company. Armed with these alarming results, Valisure then petitioned the FDA to take metformin off the U.S. market, leading to the eventual recall.
The Recall Process
The FDA recall addressed metformin makers, manufacturers, and patients. The makers named in the recall are Apotex Corp., Amneal Pharmaceuticals, Marksans Pharma Limited’s Time-Cap Labs, Inc., Lupin Pharmaceuticals Inc., and Teva Pharmaceuticals USA, Inc.’s Actavis Generics. The FDA’s announcement indicated that these five companies would be notifying wholesalers, distributors, and retailers to make arrangements for the return of the products.
The FDA also asked all companies—beyond the five named makers—that manufacture ERM to carefully monitor ongoing production and evaluate whether these products contain NDMA above the acceptable intake levels. The manufacturing companies must also test at-risk metformin lots before releasing a batch into the U.S. market. If the metformin testing indicates that NDMA is above the acceptable intake limit, the companies must inform the FDA and these batches must not be released in the market.
The FDA recommended that patients already using recalled ERM continue taking it “until a doctor or pharmacist gives them a replacement or a different treatment option.” This is meant avoid any adverse effects from a sudden stop in their metformin treatment. The FDA also urged health care professionals to prescribe ERM only when clinically appropriate, noting that testing has not found NDMA in immediate release metformin products, the most commonly prescribed type of metformin.
Pending Metformin Lawsuits
Already, lawsuits have emerged from patients potentially harmed by contaminated metformin. Metformin litigation will certainly continue to form from the millions of impacted Americans, especially after observing the surge of cases related to another NDMA-tainted drug: Zantac. Thus far, 230 Zantac claims have been consolidated in the Southern District Court of Florida and are moving into the discovery phase. Surely close behind Zantac, here are the cases already underway with metformin claims.
Class Action Against Granules USA
On March 20, 2020, an Indiana woman filed a class action on behalf of similarly situated consumers against Granules USA, Inc. and Granules Pharmaceuticals, Inc. The plaintiffs claim they were injured by paying the full purchase price for medications containing harmful levels of NDMA. The plaintiff seeks damages and restitution for a breach of the implied warranty of merchantability, unjust enrichment, fraudulent concealment, fraud, and conversion.
Healthcare Insurer Class Action
On April 3, 2020, healthcare insurer, MSP Recovery Claims, Series LLC filed a class action lawsuit on behalf of similarly-situated healthcare insurers. The suit, that names six separate pharmaceutical company defendants, seeks to recover millions of dollars in payments they allege were unlawfully solicited for contaminated metformin. The plaintiffs claim that the defendants concealed pervasive good manufacturing practice violations and defrauded the plaintiffs. The plaintiffs are demanding damages for breach of express and implied warranties, common law fraud, violations of the Florida Deceptive and Unfair Trade Practices Act, and unjust enrichment.
Expert Witnesses for Metformin Cases
Attorneys representing clients in metformin cases will rely heavily on expert witnesses for the technical aspects of alleged pharmaceutical manufacturing errors. Specialized experts in drug manufacturing processes will be needed early in a case to help attorneys understand foundational aspects of the metformin contamination. Attorneys must also consult oncology experts to understand how NDMA is linked to cancer development and the inherent health risks posed to patients. For these technical and high volume suits, experts will likely be deposed during discovery and quite possibly called to testify at trials. As these cases proceed, experts are sure to play crucial roles in assigning liability and assessing potential damages.
Expert Witness Specialty Index
Speak with an expert about the link between Metformin and cancer.
Explore a sample of our expert network.
E-570667
Pharmacology Expert Witness | New York
E-702455
Pediatric & Adult Clinical Pharmacology and Toxicology Expert Witness | Ohio
E-702886
Forensic Toxicology and Pharmacology Expert Witness | Colorado
E-538767
Psychiatric Medicine and Pharmacology Expert Witness | California
E-567387
Pharmaceuticals and Patents Expert Witness | California
E-016039
Drug Safety Expert Witness | British Columbia
About the author
Carolyn Casey, J.D.
Carolyn Casey is a seasoned professional with extensive experience in legal tech, e-discovery, and legal content creation. As Principal of WritMarketing, she combines her decade of Big Law experience with two decades in software leadership to provide strategic consulting in product strategy, content, and messaging for legal tech clients. Previously, Carolyn served as Legal Content Writer for Expert Institute, Sr. Director of Industry Relations at AccessData, and Director of Product Marketing at Zapproved, focusing on industry trends in forensic investigations, compliance, privacy, and e-discovery. Her career also includes roles at Iron Mountain as Head of Legal Product Management and Sr. Product Marketing Manager, where she led product and marketing strategies for legal services, and at Fios Inc as Sr. Marketing Manager, specializing in eDiscovery solutions.
Her early legal expertise was honed at Brobeck, Phleger & Harrison, where she developed legal strategies for mergers, acquisitions, and international finance matters. Carolyn's education includes a J.D. from American University Washington College of Law, where she was a Senior Editor for the International Law Journal and participated in a pioneering China Summer Law Program. She also holds an AB in Political Science with a minor in art history from Stanford University. Her diverse skill set encompasses research, creative writing, copy editing, and a deep understanding of legal product marketing and international legal trends.
Subscribe to our newsletter
Join our newsletter to stay up to date on legal news, insights and product updates from Expert Institute.
Sign up nowA Sample Voir Dire: How To Qualify An Expert Witness
Download free white paperChallenging Opposing Experts: Advanced Research Techniques
Download free white paperCross Examining Expert Witnesses: The Ultimate Guide
Download free white paper
Subscribe to our newsletter
Join our newsletter to stay up to date on legal news, insights and product updates from Expert Institute.